Related Experiment Video
Updated: Jun 23, 2026
09:42
Development of an Economical DNA Delivery System by "Acufection" and its Application to Skin Research
Published on: April 19, 2017
IL-4/IL-13 antagonist DNA vaccination successfully suppresses Th2 type chronic dermatitis
T Morioka1, K Yamanaka, H Mori
1Department of Dermatology, Mie University, Tsu, Japan.
The British Journal of Dermatology
|May 7, 2009
Summary
A novel therapy targeting interleukin (IL)-4/IL-13 signals, known as IL-4DM, effectively controlled atopic dermatitis (AD) in a mouse model. This treatment reduced key markers of allergic inflammation, suggesting potential for treating chronic Th2-type skin diseases.
Area of Science:
- Immunology
- Dermatology
- Molecular Biology
Background:
- Atopic dermatitis (AD) is a chronic inflammatory skin condition characterized by a dominant Th2-cytokine profile.
- Previous treatments targeting individual cytokines were limited by short biological half-lives.
- A novel dominant-negative interleukin (IL)-4/IL-13 antagonist (IL-4DM) was developed to block IL-4 and IL-13 signaling pathways.
Purpose of the Study:
- To evaluate the therapeutic efficacy of IL-4DM in an established mouse model of atopic dermatitis.
- To assess the impact of IL-4DM on key immunological and histological markers of AD.
- To determine the effects of IL-4DM on cytokine profiles in a Th2-dominant inflammatory setting.
Main Methods:
- Experimental AD-like dermatitis was induced in mice via repeated oxazolone (OX) exposure.
- Mice received intraperitoneal injections of plasmid DNA encoding IL-4DM or control constructs.
- Efficacy was assessed by measuring ear thickness, histological changes, mast cell counts, plasma IgE and histamine levels, and cytokine production in skin and splenocytes.
Main Results:
- IL-4DM treatment significantly reduced dermatitis severity, including ear swelling and thickness.
- Histological analysis revealed decreased mast cell and eosinophil infiltration in IL-4DM treated mice.
- Plasma IgE and histamine levels were suppressed, and splenocytes showed increased IFN-gamma production, indicating a shift from Th2 dominance.
Conclusions:
- Simultaneous blockade of IL-4 and IL-13 signaling pathways is a viable strategy for controlling Th2-type chronic dermatitis.
- IL-4DM DNA treatment demonstrates potent therapeutic potential for atopic dermatitis and related inflammatory conditions.
- Targeting both IL-4 and IL-13 pathways offers a promising therapeutic approach for complex allergic diseases.
Related Concept Videos
01:30Hypersensitivities
Hypersensitivity, also known as a hypersensitivity reaction or allergic reaction, is a condition where the body's immune system reacts abnormally to a foreign substance. Such substances, that cause hypersensitivity are referred to as an allergen, could be something typically harmless to most people, like pollen or certain foods.
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
01:24T Cell Types and Functions
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
01:29Hypersensitivity Reactions: Delayed Hypersensitivity Reactions
Delayed-Type Hypersensitivity (DTH), or Type IV hypersensitivity, is a cell-mediated immune response. It occurs when T cells, rather than antibodies, mediate a reaction to specific antigens. It is characterized by a delayed onset (1-2 days) and involves the recruitment of macrophages to the inflammation site.The initiation of a DTH response begins with the sensitization of T cells. During this phase, which lasts at least 1-2 weeks, antigen-specific T cells are activated, clonally expanded, and...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.